MA43231B1 - Bloqueur des canaux sodiques - Google Patents
Bloqueur des canaux sodiquesInfo
- Publication number
- MA43231B1 MA43231B1 MA43231A MA43231A MA43231B1 MA 43231 B1 MA43231 B1 MA 43231B1 MA 43231 A MA43231 A MA 43231A MA 43231 A MA43231 A MA 43231A MA 43231 B1 MA43231 B1 MA 43231B1
- Authority
- MA
- Morocco
- Prior art keywords
- sodium channel
- channel blocker
- present
- prevention
- pharmaceutically acceptable
- Prior art date
Links
- 239000003195 sodium channel blocking agent Substances 0.000 title abstract 2
- 229940125794 sodium channel blocker Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne un composé représenté par la formule chimique, ou un sel pharmaceutiquement acceptable de celui-ci. Le composé selon la présente invention peut être utilement utilisé pour la prévention ou le traitement de maladies liées aux bloqueurs des canaux sodiques.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150159637 | 2015-11-13 | ||
| PCT/KR2016/013029 WO2017082688A1 (fr) | 2015-11-13 | 2016-11-11 | Bloqueur des canaux sodiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43231B1 true MA43231B1 (fr) | 2020-08-31 |
Family
ID=58695815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43231A MA43231B1 (fr) | 2015-11-13 | 2016-11-11 | Bloqueur des canaux sodiques |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10227338B2 (fr) |
| EP (1) | EP3375782B1 (fr) |
| JP (1) | JP6559894B2 (fr) |
| KR (1) | KR102245930B1 (fr) |
| CN (1) | CN108349963B (fr) |
| AU (1) | AU2016351526B2 (fr) |
| BR (1) | BR112018009754B1 (fr) |
| CA (1) | CA3003119C (fr) |
| CL (1) | CL2018001281A1 (fr) |
| CO (1) | CO2018005064A2 (fr) |
| EC (1) | ECSP18038014A (fr) |
| ES (1) | ES2821962T3 (fr) |
| HR (1) | HRP20201695T1 (fr) |
| HU (1) | HUE052569T2 (fr) |
| MA (1) | MA43231B1 (fr) |
| MX (1) | MX376469B (fr) |
| MY (1) | MY194015A (fr) |
| NZ (1) | NZ742069A (fr) |
| PE (1) | PE20181301A1 (fr) |
| PH (1) | PH12018500999A1 (fr) |
| PL (1) | PL3375782T3 (fr) |
| PT (1) | PT3375782T (fr) |
| RS (1) | RS60927B1 (fr) |
| RU (1) | RU2705578C1 (fr) |
| SA (1) | SA518391540B1 (fr) |
| SG (1) | SG11201803867TA (fr) |
| SI (1) | SI3375782T1 (fr) |
| TN (1) | TN2018000157A1 (fr) |
| WO (1) | WO2017082688A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201903348UA (en) * | 2016-10-17 | 2019-05-30 | Genentech Inc | Therapeutic compounds and methods of use thereof |
| TW202003490A (zh) * | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| WO2020052509A1 (fr) * | 2018-09-10 | 2020-03-19 | 成都康弘药业集团股份有限公司 | Composé sulfonamide servant de bloqueur de canaux sodiques et ses utilisations |
| CN112759559B (zh) * | 2019-11-06 | 2022-08-12 | 成都康弘药业集团股份有限公司 | 作为钠通道阻滞剂的磺酰胺类化合物及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5591761A (en) * | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5464853A (en) | 1993-05-20 | 1995-11-07 | Immunopharmaceutics, Inc. | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| NZ528120A (en) * | 2001-03-12 | 2006-05-26 | Ono Pharmaceutical Co | N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same |
| JP2006290791A (ja) * | 2005-04-11 | 2006-10-26 | Astellas Pharma Inc | アゾール置換スルホニルベンゼン誘導体 |
| JP2008542219A (ja) * | 2005-05-25 | 2008-11-27 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | 疼痛処置法 |
| CA2652669A1 (fr) | 2006-06-09 | 2007-12-21 | Merck & Co., Inc. | Benzazepinones en tant que bloqueurs des canaux sodiques |
| US9422235B2 (en) * | 2006-12-19 | 2016-08-23 | Pharmos Corporation | Sulfonamide derivatives with therapeutic indications |
| SA08290245B1 (ar) | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
| JP2008290791A (ja) * | 2007-05-22 | 2008-12-04 | Funai Electric Co Ltd | 画像形成装置 |
| EP2173743A2 (fr) * | 2007-07-13 | 2010-04-14 | Icagen, Inc. | Inhibiteurs des canaux sodiques |
| HUE025013T2 (hu) * | 2009-01-12 | 2016-04-28 | Pfizer Ltd | Szulfonamid-származékok |
| CA2801032A1 (fr) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Derives de n-sulfonylbenzamide utiles comme inhibiteurs du canal sodique voltage-dependant |
| JP6014155B2 (ja) * | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| EP2788332A1 (fr) | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Inhibiteurs aryle et hétéroaryle bicycliques des canaux calciques |
| ES2593533T3 (es) | 2011-12-15 | 2016-12-09 | Pfizer Limited | Derivados de sulfonamida |
| WO2013093688A1 (fr) | 2011-12-19 | 2013-06-27 | Pfizer Limited | Dérivés sulfonamides et leur utilisation en tant qu'inhibiteurs de vgsc |
| BR112014029161A2 (pt) | 2012-05-22 | 2017-06-27 | Genentech Inc | benzamidas n-substituídas e seu uso no tratamento de dor |
| WO2014061970A1 (fr) * | 2012-10-15 | 2014-04-24 | Daewoong Pharmaceutical Co., Ltd. | Bloqueurs de canal sodique, leur procédé de préparation et leur utilisation |
| WO2015130957A1 (fr) * | 2014-02-27 | 2015-09-03 | Zalicus Pharmaceuticals, Ltd. | Inhibiteurs hétérocycliques du canal sodique |
-
2016
- 2016-11-11 EP EP16864614.9A patent/EP3375782B1/fr active Active
- 2016-11-11 KR KR1020160150511A patent/KR102245930B1/ko active Active
- 2016-11-11 US US15/771,775 patent/US10227338B2/en active Active
- 2016-11-11 RU RU2018119954A patent/RU2705578C1/ru active
- 2016-11-11 JP JP2018524451A patent/JP6559894B2/ja active Active
- 2016-11-11 BR BR112018009754-3A patent/BR112018009754B1/pt active IP Right Grant
- 2016-11-11 PT PT168646149T patent/PT3375782T/pt unknown
- 2016-11-11 CA CA3003119A patent/CA3003119C/fr active Active
- 2016-11-11 SG SG11201803867TA patent/SG11201803867TA/en unknown
- 2016-11-11 CN CN201680066269.7A patent/CN108349963B/zh active Active
- 2016-11-11 MX MX2018005940A patent/MX376469B/es active IP Right Grant
- 2016-11-11 PL PL16864614.9T patent/PL3375782T3/pl unknown
- 2016-11-11 AU AU2016351526A patent/AU2016351526B2/en active Active
- 2016-11-11 PE PE2018000765A patent/PE20181301A1/es unknown
- 2016-11-11 NZ NZ742069A patent/NZ742069A/en unknown
- 2016-11-11 TN TNP/2018/000157A patent/TN2018000157A1/en unknown
- 2016-11-11 MA MA43231A patent/MA43231B1/fr unknown
- 2016-11-11 HR HRP20201695TT patent/HRP20201695T1/hr unknown
- 2016-11-11 WO PCT/KR2016/013029 patent/WO2017082688A1/fr not_active Ceased
- 2016-11-11 ES ES16864614T patent/ES2821962T3/es active Active
- 2016-11-11 MY MYPI2018000662A patent/MY194015A/en unknown
- 2016-11-11 SI SI201630902T patent/SI3375782T1/sl unknown
- 2016-11-11 HU HUE16864614A patent/HUE052569T2/hu unknown
- 2016-11-11 RS RS20201235A patent/RS60927B1/sr unknown
-
2018
- 2018-05-08 PH PH12018500999A patent/PH12018500999A1/en unknown
- 2018-05-09 SA SA518391540A patent/SA518391540B1/ar unknown
- 2018-05-10 CL CL2018001281A patent/CL2018001281A1/es unknown
- 2018-05-11 CO CONC2018/0005064A patent/CO2018005064A2/es unknown
- 2018-05-18 EC ECIEPI201838014A patent/ECSP18038014A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51431B1 (fr) | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase | |
| ECSP20075270A (es) | Compuestos | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| MA38390A1 (fr) | Composés tétrahydropyrrolothiazines | |
| SA518400547B1 (ar) | مشتقات بيرازولو بيريميدين كمثبط كيناز | |
| PH12020551014A1 (en) | Amino-fluoropiperidine derivatives as kinase inhibitor | |
| MA46337B1 (fr) | Composé de pyridine | |
| MY196572A (en) | Amino-Methyl Piperidine Derivative as Kinase Inhibitor | |
| MA40302B1 (fr) | Dérivés de carbazole | |
| EA201892430A1 (ru) | Синтез индазолов | |
| MA40895A (fr) | Synthèse de copanlisib et son sel de dichlorhydrate | |
| WO2015101596A3 (fr) | Antagonistes du récepteur de la neurokinine 1 pour leur utilisation dans un procédé de prévention du cancer | |
| MA46039B1 (fr) | Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain | |
| ECSP18038014A (es) | Bloqueador del canal de sodio | |
| PH12019502046A1 (en) | Pyrrolotriazine derivatives as kinase inhibitor | |
| MX385570B (es) | Compuestos de fenilimidazol. | |
| MA42602B1 (fr) | Antagonistes du recepteur cgrp |